Company: LENZ
Filing Date: 2025-04-10
Form Type: CORRESP
Source: 0001628280-25-017367
Chunk: 0

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-10
Form: CORRESP
Chunk 0
---
<div align='center'>April 10, 2025</div>

#### VIA EDGAR
U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3720

Attention: Doris Stacey Gama

| Re: |     | LENZ Therapeutics, Inc.            |
|     |     | Registration Statement on Form S-3 |
|     |     | File No. 333-286398                |

#### Acceleration Request

#### Requested Date: April 14, 2025
Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as practicable

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, LENZ Therapeutics, Inc. (the “

#### Company
”) hereby requests that its Registration Statement on Form S-3 (File No. 333-286398) (the “

#### Registration Statement
”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Ben Capps at (858) 350-2237.

|     |     |                                               |     | Sincerely,              |     |                           |
|     |     |                                               |     | LENZ THERAPEUTICS, INC. |     |                           |
|     |     |                                               |     | By:                     |     | /s/ Evert Schimmelpennink |
|     |     |                                               |     |                         |     | Evert Schimmelpennink     |
|     |     |                                               |     |                         |     | Chief Executive Officer   |
| cc: |     | Daniel Chevallard, LENZ Therapeutics, Inc.    |     |                         |     |                           |
|     |     | Dan Koeppen, Wilson Sonsini Goodrich & Rosati |     |                         |     |                           |
|     |     | Ben Capps, Wilson Sonsini Goodrich & Rosati   |     |                         |     |                           |